Anne Mele, OTR in Shaftsbury, VT - Occupational Therapist

Anne Mele, OTR is a Occupational Therapist - Pediatrics based in Shaftsbury, Vermont. Anne Mele is licensed to practice in Vermont (license number 072-0000085) and her current practice location is 605 Holy Smoke Rd, Shaftsbury, Vermont. She can be reached at her office (for appointments etc.) via phone at (802) 779-8552.

NPI number for Anne Mele is 1922206549 and her current mailing address is 605 Holy Smoke Rd, Shaftsbury, Vermont. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1922206549.

Contact Information

	Anne Mele, OTR
	605 Holy Smoke Rd, Shaftsbury, VT 05262-9619
	(802) 779-8552
	Not Available

Healthcare Provider's Profile

Full Name	Anne Mele
Gender	Female
Speciality	Occupational Therapist - Pediatrics
Location	605 Holy Smoke Rd, Shaftsbury, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1922206549
Provider Enumeration Date: 07/05/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Anne Mele such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1922206549	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225XP0200X	Occupational Therapist - Pediatrics	072-0000085 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Anne Mele is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Anne Mele, OTR 605 Holy Smoke Rd, Shaftsbury, VT 05262-9619 Ph: (802) 779-8552	Anne Mele, OTR 605 Holy Smoke Rd, Shaftsbury, VT 05262-9619 Ph: (802) 779-8552

News Archive

Vytacera Pharma to develop Sulfanegen for treatment of cyanide poisoning

Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.

Survey shows alarming increase of peanut allergies in children

Results of a nationwide telephone survey have shown that the rate of peanut allergies in children more than tripled from 1997 to 2008. The data are reported in the May 12 issue of the Journal of Allergy and Clinical Immunology.

Cardiac Dimensions' enhanced version of CARILLON system receives CE Mark approval

Cardiac Dimensions, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON Mitral Contour System, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation.

Seafood mislabeling leads people to eat more sustainably, study finds

With seafood, what you see is not always what you get. It's no secret that mislabeling is rampant around the world. Recent studies estimate up to 30 percent of seafood served in restaurants and sold in supermarkets is actually something other than what is listed on the menu or label.

Anne Mele, OTR - Occupational Therapist in Shaftsbury, VT